Abstract
Normal cell cycle progression is controlled by the sequential action of cyclin-dependent kinases (CDKs), the activity of which depends on their binding to regulatory partners (cyclins). Deregulation of cell cycle is one of the first steps that transform normal cells into tumor cells. Indeed, most cancer cells bear mutations in members of the pathways that control the CDK activity. For this reason, this kinase family is a crucial target for the development of new drugs for cancer therapy. Recently, both ATP-competitive CDK inhibitors and the last generation of non-ATP-competitive inhibitors are emerging as promising agents for targeted therapies. Many clinical trials are in progress, using CDK inhibitors both as single agents and in combination with traditional cytotoxic agents. In this review, we will discuss new therapeutic strategies based on the use of CDK inhibitors in cancer.
Keywords: Cell cycle, cancer, CDKs, CDK inhibitors, anticancer therapeutics.
Current Pharmaceutical Design
Title:Anticancer Therapeutic Strategies Based on CDK Inhibitors
Volume: 19 Issue: 30
Author(s): Luca Esposito, Paola Indovina, Flora Magnotti, Daniele Conti and Antonio Giordano
Affiliation:
Keywords: Cell cycle, cancer, CDKs, CDK inhibitors, anticancer therapeutics.
Abstract: Normal cell cycle progression is controlled by the sequential action of cyclin-dependent kinases (CDKs), the activity of which depends on their binding to regulatory partners (cyclins). Deregulation of cell cycle is one of the first steps that transform normal cells into tumor cells. Indeed, most cancer cells bear mutations in members of the pathways that control the CDK activity. For this reason, this kinase family is a crucial target for the development of new drugs for cancer therapy. Recently, both ATP-competitive CDK inhibitors and the last generation of non-ATP-competitive inhibitors are emerging as promising agents for targeted therapies. Many clinical trials are in progress, using CDK inhibitors both as single agents and in combination with traditional cytotoxic agents. In this review, we will discuss new therapeutic strategies based on the use of CDK inhibitors in cancer.
Export Options
About this article
Cite this article as:
Esposito Luca, Indovina Paola, Magnotti Flora, Conti Daniele and Giordano Antonio, Anticancer Therapeutic Strategies Based on CDK Inhibitors, Current Pharmaceutical Design 2013; 19 (30) . https://dx.doi.org/10.2174/13816128113199990377
DOI https://dx.doi.org/10.2174/13816128113199990377 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chemical and Medicinal Versatility of Dithiocarbamates: An Overview
Mini-Reviews in Medicinal Chemistry Promising Targets in Anti-cancer Drug Development: Recent Updates
Current Medicinal Chemistry β -Glucans and their Applications in Cancer Therapy: Focus on human studies
Anti-Cancer Agents in Medicinal Chemistry Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Inhibiting the Interaction of cMET and IGF-1R with FAK Effectively Reduces Growth of Pancreatic Cancer Cells in vitro and in vivo
Anti-Cancer Agents in Medicinal Chemistry Impact of Metabolic Surgery on Type-2 Diabetes Remission
Current Diabetes Reviews Statins and Alkylphospholipids as New Anticancer Agents Targeting Lipid Metabolism
Anti-Cancer Agents in Medicinal Chemistry Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
Current Medicinal Chemistry Roles of Epithelial-Mesenchymal Transition in Cancer Drug Resistance
Current Cancer Drug Targets Exploiting Cyclooxygenase-(in)Dependent Properties of COX-2 Inhibitors for Malignant Glioma Therapy
Anti-Cancer Agents in Medicinal Chemistry MDM2 Increases Drug Resistance in Cancer Cells by Inducing EMT Independent of p53
Current Medicinal Chemistry The PKB/AKT Pathway in Cancer
Current Pharmaceutical Design Vitamin D and miRNAs in Cancer
Current Gene Therapy Modulation of Notch Signaling as a Therapeutic Approach for Liver Cancer
Current Gene Therapy EGFR(s) in Aging and Carcinogenesis of the Gastrointestinal Tract
Current Protein & Peptide Science Potential Uses of MicroRNA in Lung Cancer Diagnosis, Prognosis, and Therapy
Current Cancer Drug Targets The Review of the Synthesis of Bestatin, an Effective Inhibitor of Aminopeptidase N
Mini-Reviews in Organic Chemistry Epidermal Growth Factor Receptor-Targeted Therapy of Colorectal Cancer with Panitumumab
Current Cancer Therapy Reviews Generation of Human Single-chain Antibody to the CD99 Cell Surface Determinant Specifically Recognizing Ewing’s Sarcoma Tumor Cells
Current Pharmaceutical Biotechnology Targeting DNA Topoisomerase I with Non-Camptothecin Poisons
Current Medicinal Chemistry